Cybin Inc. Begins Phase 3 Trials, Betting Big On CYB003 To Treat Depression
ProMIS Neurosciences Presents Data From PMN310 Phase1a Clinical Trial At The 17th Clinical Trials On Alzheimer's Disease Conference; Results Indicated PMN310 Was Generally Well-Tolerated And Monthly Dosing Can Provide CSF Levels Adequate For Target...
Brightside Selects Helix By Q2 To Migrate BaaS Program; Brightside Offers Savings And Checking Accounts, Now Powered By Helix, To Co's To Help Employees Facing Financial Hardship
EXCLUSIVE: Neuropsychiatry-Focused Cybin Secures First US Composition of Matter Patent For Preclinical CYB005 Phenethylamines Program
What's Going On With Bright Minds Biosciences Stock?
Bright Minds Biosciences On Friday Announced US$35M Non-Brokered Private Placement @USD$21.70/Share